Insulet Posts Q2 Revenue Beat, Lifts FY22 Guidance

Comments
Loading...
  • Insulet Corporation PODD posted a Q2 net loss of $(35) million, or an EPS loss of $(0.50) compared to $(0.37) a year ago.
  • Q2 sales increased 13.8% Y/Y, or 17.7% in constant currency, to $299.4 million, exceeding the guidance range of 12%-15% in constant currency and the consensus of $291.45 million.
  • Total Omnipod automated insulin delivery system revenue was $285.8 million, +18.1%. 
  • Sales for Omnipod in the U.S. totaled $196.4 million, representing an increase of 30.5%.
  • Earlier this week, the company announced the full market launch of the latest-generation Omnipod 5 device in U.S. pharmacies.
  • Guidance: Insulet raised its FY22 revenue growth guidance to 14% - 17% from 12% - 16%.
  • The company expects growth for Omnipod sales of 18%-21% from 16% - 20% expected earlier.
  • For Q3, the forecasts sales growth of 17% - 20%, with Omnipod growth of 18% - 21%.
  • Analyst Reaction: Piper Sandler and Raymond James maintain Neutral and Outperform on Insulet, with the price target raised to $235 from $230 and $280 from $262, respectively.
  • Price Action: PODD shares closed 0.78% higher at $258.00 during after-hours trading on Thursday.
Overview Rating:
Good
62.5%
Technicals Analysis
100
0100
Financials Analysis
40
0100
Overview
Market News and Data brought to you by Benzinga APIs
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise

Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!